研究数据

<i>Escherichia coli </i>(<i>E. coli</i>) O157:H7 is a severe foodborne pathogen whose biofilm formation enhances bacterial virulence and reduces antibiotic susceptibility, often leading to the failure of traditional antibiotic treatments and posing a significant threat to human and animal health. This study utilised a constructed LuxS-eGFP reporter strain to screen for Isoferulic Acid (IFA) targeting the LuxS/AI-2 quorum sensing system (QS), revealing that IFAs can inhibit the biofilm formation of <i>E. coli </i>and enhance antibiotic susceptibility. The experimental results indicate that IFAs effectively inhibit the biofilm formation of <i>E. coli</i> without affecting bacterial growth and metabolic activity, and also demonstrate a clearance effect on mature biofilms. Building on these findings, we developed a strategy combining IFA with antibiotics, which significantly enhanced the antibacterial efficacy of sodium fosfomycin against <i>E. coli</i> both in vitro and in vivo. These findings confirm that IFA exhibits significant antibiofilm activity and novel synergistic antibacterial effects, providing a potential new strategy for treating <i>E. coli </i>infections.大肠埃希菌（Escherichia coli，E. coli）O157:H7是一种高致病性食源性致病菌，其生物被膜形成可增强细菌毒力并降低抗生素敏感性，常导致传统抗生素治疗失败，对人和动物健康构成严重威胁。本研究利用构建的LuxS-eGFP报告菌株，针对LuxS/AI-2群体感应系统（QS）筛选异阿魏酸（Isoferulic Acid，IFA），结果显示异阿魏酸可抑制大肠埃希菌的生物被膜形成并提升其抗生素敏感性。实验结果表明，异阿魏酸可在不影响细菌生长与代谢活性的前提下，有效抑制大肠埃希菌生物被膜形成，同时对成熟生物被膜具有清除作用。基于上述研究结果，本团队开发了一种异阿魏酸与抗生素联合应用的策略，该策略可在体外与体内环境中显著增强磷霉素钠（sodium fosfomycin）对抗大肠埃希菌的抗菌效果。本研究证实，异阿魏酸具有显著的抗生物被膜活性与新型协同抗菌作用，为大肠埃希菌感染的治疗提供了潜在的全新策略。